Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of two synthetic peptides, referred to as "4-peptide" and "12-peptide." The names suggest that one peptide consists of four amino acids and the other of twelve amino acids. Peptides in this size range are considered short-chain peptides and may be used for therapeutic purposes, such as mimicking natural hormones, growth factors, or signaling molecules[2][3]. However, there is no evidence from the provided sources that "4-peptide + 12-peptide" refers to a specific approved pharmaceutical product or widely recognized investigational drug. In general, peptide therapeutics can act via various mechanisms depending on their sequence and target; they are often well-tolerated due to their metabolic compatibility with human physiology[3]. Without further information about the sequences or intended use of these peptides, detailed mechanism(s) cannot be specified.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 4-peptide + 12-peptide.